The LifEscozul™ Group is the leading company in the investigation of the medical properties of the Blue Scorpion Venom as well as in Clinical Results and Medical Research with the most advanced formulation of the blue scorpion venom: LifEscozul™
Composed of Cuban doctors and scientists, we are in the final phase of sanitary registration, through research agreements with universities and laboratories from Chile, and Mexico.
With more than 500 published positive results, our Medical Protocol is highly specialized. The treatment is personalized, and we follow a changing dose regimen according to the results. Each patient has a doctor and a scientific advisor assigned from the start of treatment.
We are the only company that certifies each sample in FDA certified laboratories. This ensures that the patient receives a dose with the highest safety standards.
It is important to know that LifEscozul™/ Escozul® is not a commercial product, nor can it be freely distributed or commercialized. Before entering the Protocol, each case must be analyzed by a Medical Committee. All shipments are made directly from our laboratories with prior medical approval.
About new agreements reached in Mexico with —
Pharmometrica y Research Pro SC — for the development of the Escozul® project.
The LifEscozul™ Group is composed of more than 25 Cuban specialists in different branches of medicine and science.
We invite you to meet our specialists, their profiles, and their curriculum. Our biologists, physicians, and biochemists are here to offer their knowledge and experience. Led by Dr. Alexis Diaz, the highest authority on scorpion venom research, our team understands the enormous value of offering straightforward and simple explanations of the Protocol, Investigations, and Results. We believe that it is important for you to know Who We Are with absolute transparency.
More than 500 positive clinical results with the advanced formula of the blue scorpion venom, LifEscozul™, make us the leading company in results. Escozul®.
The LifEscozul™ Group publishes clinical cases showing our patients' evolution during the Protocol and medical follow-up.
Every week we interview our patients via videoconferences to tell their stories and serve as inspiration. Many of these patients have been in Protocol for more than 2 years and have stories to tell.
We invite you to know these stories. And how LifEscozul™ has changed these lives.
Alexis Díaz, PhD
Research and Development Department
Dr. Alexis Díaz is the director of the Research and Development Department of the LifEscozul™ Group.
With 17 years of experience and the author of more than 25 scientific articles on the venom of the blue scorpion, he is considered the highest scientific authority on the subject.
Currently, the Research and Development Department is in charge of the development of scientific research in coordination with several universities attached to the Project to achieve the corresponding sanitary registration, as well as the patent for the LifEscozul™ formulation, the most advanced and effective formulated with the venom of the blue scorpion.
Another project is to develop a synthetic formulation of the venom of the blue scorpion by identifying the fundamental components of the active principle.
Da. Mariela Guevara
Dr. Mariela Guevara is the Senior Advisor for the LifEscozul™ Group's Clinical Trials to be carried out in 2022.
As part of the Health Registration process, she is in charge of developing the protocols for clinical trials.
Dr. Mariela Guevara has vast experience in leading clinical trials and more than 10 years working with the blue scorpion venom.
The LifEscozul™ Group currently coordinates 12 research projects, including preclinical research, clinical trials, toxicology, protein purification and identification, and synthesis of the antitumor compounds present in the venom of the blue scorpion (Escozul®).
These studies are carried out in coordination with the most prestigious universities in Chile and with laboratories with FDA regulations.
We invite you to know about these projects.
The LifEscozul™ Group is the only company that actively seeks the first sanitary registration in the most advanced formulation of blue scorpion venom.
The University of Talca, Chile, and the LifEscozul™ Group sign their first mutual agreement. At the University of Talca, Chile, the following experiments will be carried out:
Total protein quantification, cell viability, in vitro cell toxicity and studies of thermal and enzymatic stability of the venom of the blue scorpion (Rhopalurus junceus) through a provision of services for the LifEscozul Group (Link article). The results of the investigation will be reported on this page.
4.62 Rating More than 1500 ReviewsAll Opinions
of our patients